期刊文献+

Cancer vaccines:shared tumor antigens return to the spotlight

原文传递
导出
摘要 Sahin et al.recently reported interim data from a phase 1 clinical trial(NCT02410733)treating melanoma patients with a RNAlipoplex vaccine(RNA-LPX),targeting melanoma TAA.1 The trial is a multicenter,non-randomized,open-label,dose-escalation trial designed to evaluate the safety and tolerability of BNT111 targeting four melanoma TAA(NY-ESO-1,MAGE-A3,tyrosinase,and TPTE).Secondary endpoints include vaccine-induced immune responses and clinical response of patients with measurable disease.
出处 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2020年第1期324-325,共2页 信号转导与靶向治疗(英文)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部